Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
Image credit: Damir Khabirov | stock.adobe.com
A single intravenous (IV) infusion of Lundbeck’s investigational agent Lu AG09222 achieved superiority over placebo in lowering the frequency of migraine headaches over the following four weeks, according to the results of the Phase IIa HOPEtrial (NCT05133323) published by The New England Journal of Medicine.1,2 Lu AG09222, pituitary adenylate cyclase-activating polypeptide (PACAP)-targeting therapy, demonstrated efficacy for this patient population in prior clinical research.3
“Experimental studies have shown that intravenous infusion of PACAP induces migraine attacks in persons with migraine. Blocking PACAP signaling may therefore constitute a promising drug target for migraine prevention,” the study authors wrote. “Lu AG09222 is a humanized monoclonal antibody that binds to both isoforms of PACAP and inhibits their receptor-mediated signaling. Experiments in animals have shown that Lu AG09222 prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine in rodent models. Furthermore, a recent phase I trial involving healthy volunteers showed that pretreatment with Lu AG09222 can inhibit PACAP-induced dilation of cranial arteries and reduce concomitant headache.”1
Lu AG09222 is delivered via IV infusion and binds to the PACAP ligand with high affinity, thereby inhibiting PACAP from activating its receptors and stopping PACAP-induced arterial dilation.3
"Initiation of this phase IIb trial of Lu AG09222 further progresses our neurology pipeline and emphasizes Lundbeck’s commitment to people living with migraine and headache-related disorders,” said Johan Luthman, executive vice president, and head of Research and Development at Lundbeck, in a prior press release. "The diverse nature of the disease highlights the need for exploring novel therapeutic approaches that can address unmet needs. Lu AG09222 has a good chance of being first-in-class with this interesting mechanism."3
The multicenter, double-blind, randomized, placebo-controlled HOPE trial screened 337 adults, aged 18 to 65 years, of whom 237 underwent randomization and 233 were included in the full analysis population. Investigators sought to determine whether inhibiting PACAP signaling with Lu AG09222 is effective in migraine prevention.
Patients were randomly assigned in a 2:1:2 ratio to receive either 750 mg of Lu AG09222, 100 mg of Lu AG09222, or placebo. The trial’s primary endpoint was mean change from baseline in number of monthly migraine days during weeks one through four in the Lu AG09222 750 mg cohort compared to placebo.
Among the participants, 97 were administered 750 mg of Lu AG09222, 46 were administered 100 mg of Lu AG09222, and 94 were administered placebo. In the overall trial population, the mean number of baseline migraine days per month was 16.7. Mean change from baseline from weeks one through four was −6.2 days in the Lu AG09222 750 mg cohort compared to −4.2 days in the placebo cohort (difference, −2.0 days; 95% confidence interval, −3.8 to −0.3; P=0.02).
In terms of safety, there were a higher incidence of adverse events (AEs) in the Lu AG09222 750 mg cohort compared to placebo across the 12-week observation period. The most frequently reported AEs included COVID-19 (7% in the treatment cohort vs. 3% with placebo), nasopharyngitis (7% vs. 4%), and fatigue (5% vs. 1%).
“In this trial involving persons with migraine, a one-time 750-mg infusion of Lu AG09222 showed superiority over placebo in reducing the number of migraine days per month over the subsequent 4 weeks,” the study authors concluded. “This finding establishes proof of concept, supporting the notion that inhibition of PACAP signaling by Lu AG09222 represents a potentially effective mechanism for migraine prevention. Longer trials are warranted to ascertain the efficacy and safety of Lu AG09222 in persons with migraine.”1
References
1. Ashina, M., et al. A Monoclonal Antibody to PACAP for Migraine Prevention. Published September 4, 2024. N Engl J Med 2024;391:800-809. DOI: 10.1056/NEJMoa2314577. Vol. 391 No. 9.
2. A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments. ClinicalTrials.gov. March 13, 2024. Accessed September 5, 2024. https://clinicaltrials.gov/study/NCT05133323
3. Lundbeck’s potential first-in-class therapy for migraine prevention enters advanced clinical stage. News release. Lundbeck. March 15, 2024. Accessed September 5, 2024. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://mb.cision.com/Main/18215/3945776/2669590.pdf
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.